Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer
The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer
May 24, 2019 -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2019 Category: Drugs & Pharmacology Source Type: news
Cognitive-Behavioral Therapy Reduces Endocrine Tx Side Effects Cognitive-Behavioral Therapy Reduces Endocrine Tx Side Effects
Cognitive-behavioral therapy may offer breast cancer patients an option to manage the side effects of adjuvant endocrine therapy, according to a new study.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news
Ibrance Approval Expanded to Include Men With Breast Cancer
Kinase inhibitor approved in combination with endocrine therapy for male patients with breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 5, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news
FDA expands approved use of metastatic breast cancer treatment to include male patients
The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 4, 2019 Category: American Health Source Type: news
FDA expands approved use of metastatic breast cancer treatment to include male patients
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: World Pharma News)
Source: World Pharma News - April 4, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Surgery Tied To 44% Increased Survival In Women With Advanced Breast Cancer
(CNN) — Surgery is tied to improved chances of survival among stage 4 breast cancer patients, a new study suggests, but who has access to surgery and who doesn’t can vary drastically, based on factors including income level and where treatment is administered.
Surgery to remove tumors was associated with a 44% increased chance of survival within an average followup period of 21 months, according to the abstract, to be presented at the American Association for Cancer Research’s annual meeting in Atlanta this week.
“If breast surgery is to be considered by patients and providers when deciding treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer CNN Source Type: news
FFNP-PET could aid breast cancer treatment evaluation
PET imaging with fluoro furanyl norprogesterone (FFNP) could provide a new...Read more on AuntMinnie.comRelated Reading:
JNM: Imaging agents predict endocrine therapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 12, 2019 Category: Radiology Source Type: news
Endocrine Tx Does Not Impair Neuropsychological Performance
WEDNESDAY, Dec. 19, 2018 -- For early-stage breast cancer survivors, endocrine therapy (ET) appears to have no effect on neuropsychological performance or impairment over six years of follow-up, according to a study published online Nov. 28 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 19, 2018 Category: Pharmaceuticals Source Type: news
Surgery or Endocrine Therapy for Breast CA in Older Women? Surgery or Endocrine Therapy for Breast CA in Older Women?
Dr Lowenfels challenges the findings of a recent study that suggests surgery as the better option in treating older women with early-stage breast cancer.Medscape General Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2018 Category: Consumer Health News Tags: General Surgery Viewpoint Source Type: news
UCLA research suggests widely used breast cancer therapy doesn ’t cause cognitive decline
UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.Endocrine therapy has become an essential part of treatment for the many women diagnosed with hormone-receptor positive breast cancer, in which hormones, such as estrogen, promote cancer growth. The endocrine treatment helps lower the recurrence and reduce the risk of death from breast cancer by interfering with how a woman ’s own hormones can continue to support the growth of dormant cancer cells. Yet, there has been limited evidence on w...
Source: UCLA Newsroom: Health Sciences - November 28, 2018 Category: Universities & Medical Training Source Type: news
Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Black women more likely to skip crucial breast cancer treatments
(Oxford University Press USA) A new study in the Journal of the National Cancer Institute finds that black women are more likely to skip hormone therapy treatments, also known as endocrine therapy, for breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2018 Category: Cancer & Oncology Source Type: news
MONALEESA-3 Expands Endocrine Tx for Advanced Breast Cancer MONALEESA-3 Expands Endocrine Tx for Advanced Breast Cancer
The MONALEESA-3 trial marks an important step forward for endocrine therapies for advanced breast cancer, argues Lidia Schapira.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
Obese Breast Cancer Patients and Survivors: Management Considerations
This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Jennifer Y. Sheng, MD, Dipali Sharma, MS, PhD, Gerald Jerome, PhD, Cesar Augusto Santa-Maria, MD Source Type: news
